Therefore, the skewness and 10th percentile of first-order features at baseline level could be used to predict the efficacy in EGFR-mutant advanced lung adenocarcinoma following standard first-line EGFR-TKI therapy. The gene discussed is EGFR; the disease is lung adenocarcinoma.